Polypharmacy: A Comprehensive Review of Prevalence, Mechanisms, Consequences, and Management Strategies

Abstract

Polypharmacy, generally defined as the concurrent use of five or more medications, is a growing global health concern, particularly within aging populations and individuals with multiple chronic conditions. While medication use is often necessary to manage complex health needs, the increased risk of adverse drug events (ADEs), drug-drug interactions (DDIs), non-adherence, and escalating healthcare costs associated with polypharmacy necessitates a comprehensive understanding of its underlying mechanisms, clinical consequences, and effective management strategies. This report provides an in-depth review of polypharmacy, exploring its prevalence across different populations, the multifaceted mechanisms driving its development, the diverse clinical outcomes linked to its use, and evidence-based interventions aimed at optimizing medication management and deprescribing. It further examines the challenges in defining and measuring polypharmacy, the role of technology and artificial intelligence in medication safety, and future research directions to mitigate the risks associated with polypharmacy and improve patient outcomes.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

The demographic shift towards an aging global population, coupled with the increasing prevalence of chronic diseases, has led to a significant rise in polypharmacy. While the use of multiple medications is frequently essential for managing complex health conditions, the potential for adverse drug events (ADEs), drug-drug interactions (DDIs), reduced adherence, and increased healthcare expenditures makes polypharmacy a critical area of concern for clinicians, researchers, and policymakers. Furthermore, the definition of polypharmacy itself varies across studies, with some using a threshold of five or more medications, while others define it more broadly, further complicating prevalence comparisons and interpretation of research findings. This report aims to provide a comprehensive overview of polypharmacy, encompassing its prevalence, underlying mechanisms, clinical consequences, and evidence-based management strategies. We will critically evaluate current research, highlight existing gaps in knowledge, and propose future directions for improving the safety and effectiveness of medication use in patients requiring multiple medications.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Defining and Measuring Polypharmacy: Challenges and Considerations

Defining polypharmacy is not as straightforward as simply counting the number of medications a patient takes. While the numerical threshold of five or more medications is commonly used, this definition fails to account for the potential complexity of medication regimens, the specific types of drugs involved, and individual patient characteristics. Alternative definitions of polypharmacy may include the use of specific combinations of medications (e.g., concurrent use of opioids and benzodiazepines), the use of medications with a high risk of adverse events in older adults (e.g., anticholinergics), or the presence of potentially inappropriate medications (PIMs) according to established criteria like the Beers criteria or STOPP/START criteria [1, 2].

The method of data collection also affects the measurement of polypharmacy. Data can be obtained from patient self-reports, electronic health records (EHRs), pharmacy claims data, and medication reconciliation. Each method has its limitations. Self-reported medication lists may be incomplete or inaccurate due to recall bias or lack of awareness of all medications being taken. EHR data may not capture medications obtained from multiple healthcare providers or over-the-counter medications. Pharmacy claims data may not reflect actual medication adherence or discontinuation. Medication reconciliation, while considered the gold standard, can be resource-intensive and may not always be feasible in all clinical settings.

Therefore, a more nuanced approach to defining and measuring polypharmacy is needed, one that considers both the number of medications and the complexity of the medication regimen, along with individual patient factors and the method of data collection. Future research should focus on developing more sophisticated measures of polypharmacy that better reflect the clinical risk associated with the use of multiple medications.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Prevalence of Polypharmacy: Variations Across Populations and Settings

The prevalence of polypharmacy varies widely depending on the population studied, the definition of polypharmacy used, and the setting in which the data are collected. Older adults are particularly vulnerable to polypharmacy due to age-related physiological changes that affect drug metabolism and excretion, as well as the increased prevalence of chronic conditions [3]. Studies have shown that the prevalence of polypharmacy in older adults ranges from 20% to over 60% [4].

Individuals with multiple chronic conditions, such as diabetes, cardiovascular disease, and chronic kidney disease, are also at high risk of polypharmacy. In these populations, the use of multiple medications is often necessary to manage the various aspects of their underlying diseases. Furthermore, certain populations, such as residents of long-term care facilities and patients receiving palliative care, have particularly high rates of polypharmacy due to the complex medical needs of these individuals. The complexity of care required by these individuals increases the likelihood of them receiving multiple medications simultaneously.

Geographic variations in polypharmacy prevalence have also been reported, potentially reflecting differences in prescribing practices, healthcare access, and cultural attitudes towards medication use. Understanding these variations is crucial for tailoring interventions to address the specific needs of different populations. For example, a rural community may have reduced access to specialist healthcare which has implications on a patient receiving care for co-morbidities and therefore influences the likelihood of being treated with multiple medications.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Mechanisms Driving Polypharmacy: A Multifactorial Perspective

Polypharmacy is rarely the result of a single factor but rather a complex interplay of patient-related, provider-related, and system-related factors. Patient-related factors include the presence of multiple chronic conditions, age-related physiological changes, cognitive impairment, and patient preferences. Provider-related factors include prescribing cascade (where a medication is prescribed to treat the side effect of another medication), lack of medication review, inadequate communication between healthcare providers, and adherence to clinical guidelines that promote the use of multiple medications. System-related factors include fragmented healthcare delivery, lack of access to comprehensive medication management services, and financial incentives that favor prescribing over deprescribing. The increasing specialisation of medical professionals can also contribute as the number of specialists prescribing medication to the same patient can lead to polypharmacy if there is a lack of communication.

The prescribing cascade is a particularly insidious mechanism contributing to polypharmacy. For example, a patient taking a diuretic for hypertension may develop urinary incontinence as a side effect. Instead of deprescribing the diuretic or exploring alternative antihypertensive medications, the physician may prescribe an anticholinergic medication to treat the incontinence, potentially leading to a cascade of further adverse effects and medication additions. The patient may develop constipation or blurred vision from the anti-cholinergic medication that will require further treatment. This cascade not only increases the number of medications the patient is taking but also exposes them to the risks associated with each additional drug.

Addressing polypharmacy requires a multifaceted approach that targets these various factors, including patient education, provider training, improved communication and coordination of care, and the implementation of comprehensive medication management services. Patient education should not be underestimated; a better understanding of the potential harms associated with polypharmacy can make the patient more willing to discuss their medications with their healthcare providers and explore deprescribing options.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Clinical Consequences of Polypharmacy: A Spectrum of Adverse Outcomes

Polypharmacy is associated with a wide range of adverse clinical outcomes, including adverse drug events (ADEs), drug-drug interactions (DDIs), reduced medication adherence, increased risk of falls, cognitive impairment, hospitalizations, and mortality [5]. The risk of ADEs increases exponentially with the number of medications a patient is taking [6]. DDIs can alter the pharmacokinetic or pharmacodynamic properties of medications, leading to unpredictable and potentially serious consequences.

Polypharmacy can also negatively impact medication adherence. Patients taking multiple medications may find it difficult to keep track of their medication schedules, leading to missed doses or incorrect administration. This can result in suboptimal treatment outcomes and increased healthcare costs. The more complex the regimen, the more difficult it will be for the patient to adhere to the regimen.

Falls are a significant concern in older adults, and polypharmacy is a major risk factor for falls. Certain medications, such as sedatives, antidepressants, and antihypertensives, can increase the risk of falls by causing dizziness, orthostatic hypotension, and impaired balance. Falls can lead to serious injuries, such as fractures and head trauma, and can significantly impact quality of life.

Cognitive impairment is another potential consequence of polypharmacy. Certain medications, such as anticholinergics and benzodiazepines, can impair cognitive function, particularly in older adults with pre-existing cognitive decline. This can lead to confusion, memory problems, and impaired decision-making.

Finally, polypharmacy has been linked to increased rates of hospitalizations and mortality. ADEs and DDIs can lead to serious medical complications that require hospitalization. In some cases, polypharmacy can directly contribute to mortality, particularly when it involves the use of high-risk medications or when medications are not appropriately managed. The clinical consequences of polypharmacy extend beyond the individual patient. The increased risk of ADEs, hospitalizations, and mortality associated with polypharmacy place a significant burden on the healthcare system, leading to increased costs and resource utilization. It is imperative that healthcare providers recognize the potential risks of polypharmacy and take steps to minimize its occurrence and mitigate its consequences.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Drug-Drug Interactions: A Critical Consideration in Polypharmacy

Drug-drug interactions (DDIs) are a significant concern in patients receiving multiple medications. DDIs can occur through various mechanisms, including pharmacokinetic interactions (affecting drug absorption, distribution, metabolism, or excretion) and pharmacodynamic interactions (affecting drug action at the receptor level) [7].

Pharmacokinetic interactions can alter the concentration of a drug in the body, leading to either increased or decreased drug effects. For example, the co-administration of a CYP3A4 inhibitor (e.g., clarithromycin) with a CYP3A4 substrate (e.g., simvastatin) can increase the plasma concentration of simvastatin, leading to an increased risk of myopathy. Conversely, the co-administration of a CYP3A4 inducer (e.g., rifampin) with a CYP3A4 substrate can decrease the plasma concentration of the substrate, potentially leading to treatment failure.

Pharmacodynamic interactions occur when two or more drugs have additive, synergistic, or antagonistic effects on the same physiological system. For example, the co-administration of two central nervous system (CNS) depressants, such as opioids and benzodiazepines, can have additive depressant effects, leading to increased sedation, respiratory depression, and risk of overdose. Conversely, the co-administration of a beta-blocker with a beta-agonist can have antagonistic effects, potentially blunting the effects of both drugs.

Identifying and managing DDIs requires a thorough understanding of drug pharmacology and potential interaction mechanisms. Healthcare providers should use drug interaction databases and other resources to screen for potential DDIs before prescribing or dispensing medications. When DDIs are identified, strategies to manage the interaction may include dose adjustments, medication substitutions, or careful monitoring for adverse effects.

The availability of pharmacogenomic information can also aid in the identification and management of DDIs. Pharmacogenomics involves studying how genes affect a person’s response to drugs. Genetic variations in drug-metabolizing enzymes, drug transporters, and drug targets can influence the risk of DDIs. By identifying patients with genetic variations that predispose them to DDIs, healthcare providers can tailor medication regimens to minimize the risk of adverse outcomes.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Deprescribing: A Systematic Approach to Medication Optimization

Deprescribing is the planned and supervised process of dose reduction or discontinuation of medications that are no longer needed or may be causing harm. It is an essential component of comprehensive medication management and can help to reduce the burden of polypharmacy and improve patient outcomes [8]. Deprescribing should be considered for patients who are taking multiple medications, experiencing adverse drug events, or have conditions that have resolved or are no longer being actively treated.

The deprescribing process typically involves a thorough medication review to identify medications that are potentially inappropriate, unnecessary, or causing harm. The healthcare provider should consider the patient’s medical history, current health status, and individual preferences when making deprescribing decisions. The healthcare provider should also take into account the potential risks and benefits of deprescribing each medication.

Once medications have been identified for potential deprescribing, a deprescribing plan should be developed in collaboration with the patient. The plan should specify the dose reduction or discontinuation schedule for each medication, as well as the monitoring parameters to assess the effects of deprescribing. The deprescribing process should be gradual and individualized to minimize the risk of withdrawal symptoms or rebound effects.

Patient education is a crucial component of the deprescribing process. Patients should be informed about the rationale for deprescribing, the potential benefits and risks, and the monitoring plan. Patients should also be encouraged to actively participate in the deprescribing process and to communicate any concerns or adverse effects to their healthcare provider.

Several tools and resources are available to assist healthcare providers with deprescribing, including deprescribing guidelines, algorithms, and decision support tools. These tools can help to identify medications that are potentially inappropriate, provide guidance on dose reduction or discontinuation strategies, and offer monitoring recommendations.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

8. Medication Management Strategies: Optimizing Medication Use and Safety

Effective medication management strategies are essential for minimizing the risks associated with polypharmacy and optimizing medication use. These strategies include comprehensive medication reviews, medication reconciliation, patient education and counseling, and interprofessional collaboration.

Comprehensive medication reviews involve a thorough assessment of the patient’s medication regimen, including prescription medications, over-the-counter medications, and herbal supplements. The goal of the medication review is to identify any potential problems, such as drug-drug interactions, adverse drug events, or medication non-adherence. The medication review should also assess the appropriateness of each medication, considering the patient’s medical history, current health status, and individual preferences.

Medication reconciliation is the process of comparing the patient’s medication list with the medications they are actually taking. This process is particularly important during transitions of care, such as hospital admission or discharge, to ensure that the patient’s medication list is accurate and up-to-date. Medication reconciliation can help to prevent medication errors and adverse drug events.

Patient education and counseling are crucial for promoting medication adherence and ensuring that patients understand how to take their medications safely and effectively. Patients should be provided with clear and concise information about the purpose of each medication, the potential side effects, and any special instructions for taking the medication. Patients should also be encouraged to ask questions and to communicate any concerns or adverse effects to their healthcare provider.

Interprofessional collaboration involves the collaboration of healthcare professionals from different disciplines, such as physicians, pharmacists, nurses, and social workers, to provide comprehensive medication management services. This collaborative approach can help to improve communication, coordination of care, and medication safety.

The use of technology and electronic health records (EHRs) can also play a significant role in improving medication management. EHRs can provide healthcare providers with access to comprehensive patient information, including medication lists, allergy information, and laboratory results. EHRs can also be used to generate alerts for potential drug-drug interactions, adverse drug events, and other medication-related problems.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

9. The Role of Technology and Artificial Intelligence in Medication Safety

Technology is playing an increasingly important role in improving medication safety and reducing the risks associated with polypharmacy. Electronic health records (EHRs), clinical decision support systems (CDSSs), and artificial intelligence (AI) are all being used to enhance medication management and prevent medication errors.

EHRs provide healthcare providers with access to comprehensive patient information, including medication lists, allergy information, and laboratory results. This information can be used to identify potential drug-drug interactions, adverse drug events, and other medication-related problems. EHRs can also be used to track medication adherence and to monitor the effects of medications.

CDSSs are computer-based tools that provide healthcare providers with evidence-based recommendations for medication management. CDSSs can be used to generate alerts for potential drug-drug interactions, adverse drug events, and other medication-related problems. CDSSs can also provide guidance on dose adjustments, medication substitutions, and other medication management strategies.

AI is being used to develop new tools and technologies for improving medication safety. For example, AI algorithms can be used to predict the risk of adverse drug events, to identify patients who are at high risk of medication non-adherence, and to personalize medication regimens. AI can also be used to automate medication reconciliation and other medication management tasks.

The use of technology and AI in medication safety has the potential to significantly reduce the risks associated with polypharmacy and to improve patient outcomes. However, it is important to ensure that these technologies are used appropriately and that healthcare providers are adequately trained in their use. It is also important to address any potential ethical and privacy concerns associated with the use of technology and AI in healthcare.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

10. Future Directions and Research Needs

Despite significant advances in our understanding of polypharmacy, there remain many unanswered questions and areas for future research. Future research should focus on developing more precise definitions and measures of polypharmacy, identifying risk factors for polypharmacy, evaluating the effectiveness of different interventions for managing polypharmacy, and developing new technologies for improving medication safety.

Further research is needed to develop more precise definitions and measures of polypharmacy. The current definition of polypharmacy, which is based on the number of medications a patient is taking, does not adequately capture the complexity of medication regimens. Future research should focus on developing measures of polypharmacy that take into account the types of medications being taken, the potential for drug-drug interactions, and the patient’s individual risk factors.

More research is also needed to identify risk factors for polypharmacy. Understanding the factors that contribute to polypharmacy can help to identify patients who are at high risk and to target interventions accordingly. Risk factors for polypharmacy may include age, chronic disease, cognitive impairment, and social isolation.

Future research should also evaluate the effectiveness of different interventions for managing polypharmacy. These interventions may include comprehensive medication reviews, medication reconciliation, patient education and counseling, and deprescribing. The research should assess the impact of these interventions on patient outcomes, such as adverse drug events, hospitalizations, and mortality.

Finally, future research should focus on developing new technologies for improving medication safety. These technologies may include AI-powered tools for predicting the risk of adverse drug events, identifying patients who are at high risk of medication non-adherence, and personalizing medication regimens.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

11. Conclusion

Polypharmacy is a complex and growing global health concern with significant implications for patient safety, healthcare costs, and overall well-being. Understanding the prevalence, mechanisms, and consequences of polypharmacy is essential for developing effective strategies to optimize medication management and reduce the risk of adverse outcomes. A multifaceted approach, including comprehensive medication reviews, medication reconciliation, patient education, and interprofessional collaboration, is crucial for addressing the challenges of polypharmacy. Furthermore, leveraging technology and artificial intelligence can enhance medication safety and personalize treatment approaches. Future research should focus on refining definitions of polypharmacy, identifying risk factors, evaluating the effectiveness of interventions, and developing innovative solutions to mitigate the risks associated with polypharmacy and improve patient outcomes. Ultimately, a proactive and collaborative approach is needed to ensure that medications are used safely and effectively, maximizing their benefits while minimizing their potential harms.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

[1] Beers MH. Explicit criteria for determining potentially inappropriate medication use in older adults. Arch Intern Med. 1997;157(14):1531-6.
[2] O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213-8.
[3] Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57-65.
[4] Onder G, Liperoti R, Fialova D, et al. Polypharmacy in elderly populations: results of the ICARE study. Aging Clin Exp Res. 2006;18(2):114-9.
[5] Shah BM, Hanlon JT. Polypharmacy: what is it and what matters. Age Ageing. 2011;40(6):614-6.
[6] Davies NM, Reeve E, Hilmer SN, Redfern J, Gnjidic D. Adverse outcomes of polypharmacy in older people: systematic review and meta-analysis. J Am Med Dir Assoc. 2020;21(2):181-7.
[7] Tatro DS. Drug Interaction Facts. St Louis, MO: Facts and Comparisons; 2005.
[8] Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging definition of ‘deprescribing’ with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol. 2015;80(6):1254-68.